Secondary C805S Mutation in HER2 Gene Confers Acquired Resistance to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer

被引：0
|
作者：
Kosaka, Takayuki [1 ]
Endoh, Hideki [1 ]
Repellin, Claire [1 ]
Tanizaki, Junko [1 ]
Ercan, Dalia [1 ]
Capelletti, Marzia [1 ]
Jaenne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
HER2; NSCLC; Acquired resistance; Target therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI09.08
引用
收藏
页码：S296 / S296
页数：1
相关论文
共 50 条
  • [21] A novel HER2 gene body enhancer contributes to HER2 expression
    Q Liu
    M V Kulak
    N Borcherding
    P K Maina
    W Zhang
    R J Weigel
    H H Qi
    Oncogene, 2018, 37 : 687 - 694
  • [22] HER2 gene amplification in HER2 2+breast cancer and its clinicopathological characteristics
    Wan, Dan
    Wang, Xi
    Zhang, Yu -Tao
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 1097 - 1098
  • [23] Evaluating HER2 status using HER2 Gene Protein Assay in Endometrial Cancer
    Shafi, Saba
    Parwani, Anil
    Li, Zaibo
    Nitta, Hiro
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 824 - 825
  • [24] Evaluating HER2 status using HER2 Gene Protein Assay in Endometrial Cancer
    Shafi, Saba
    Parwani, Anil
    Li, Zaibo
    Nitta, Hiro
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 824 - 825
  • [25] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [26] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [27] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [28] Calmodulin binds HER2 and modulates HER2 signaling
    White, Colin D.
    Li, Zhigang
    Sacks, David B.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2011, 1813 (05): : 1074 - 1082
  • [29] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [30] Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
    Koga, Takamasa
    Suda, Kenichi
    Nishino, Masaya
    Fujino, Toshio
    Ohara, Shuta
    Hamada, Akira
    Soh, Junichi
    Tirunagaru, Vijaya
    Vellanki, Avanish
    Doebele, Robert C.
    Mitsudomi, Tetsuya
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (08) : 3659 - +
12345